Amplification of immune T lymphocyte function in situ: the identification of active components of the immunologic network during tumor rejection.
Antigen-Presenting-Cells: im, Antigens-Immune-Response, Graft-Rejection, Interleukin-1: bi, Interleukin-2: bi, Lymphocyte-Transformation, Macrophages: cl, me, Male, Mice, Mice-Inbred-C57BL, Phenotype, Rhabdomyosarcoma: im, th, SUPPORT-NON-U-S-GOVT, SUPPORT-U-S-GOVT-P-H-S, T-Lymphocytes: im, me
J-Immunol. 1985 Aug; 135(2):1498-504.
Previous data had indicated that sarcoma-bearing mice receiving combination therapy consisting of a single i.p. injection of cytoxan (CY) and an i.v. injection of tumor-sensitized T cells (immune cells) rejected the neoplasm. The reaction was immunologically specific and dependent on donor T cells. This report is concerned with the hypothesis that the transfer of immune cells results in the amplification of T cell responses at the tumor site. Using C57BL/6J mice bearing the syngeneic rhabdomyosarcoma MCA/76-9, we show that 6 to 9 days after combination therapy those components usually associated with the immunologic network were present at the tumor site. Tumor-associated macrophages (TAM) and lymphocytes (TAL) were shown to produce IL 1 and IL 2, respectively. The TAM expressed Ir gene products (Ia) and were able to present the synthetic polymer GAT to specifically sensitized lymphocytes. In addition, it was demonstrated by in situ labeling with 3H-TdR that lymphocytes associated with the regressing tumors were proliferating. The peak incorporation occurred 7 days after therapy, 24 hr before a significant increase in the T cell content of the tumors. The data indicate that those facets of the immunologic network necessary for amplification were present at the site of rejection.
Amplification of immune T lymphocyte function in situ: the identification of active components of the immunologic network during tumor rejection. J-Immunol. 1985 Aug; 135(2):1498-504.